Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase III for Solid Tumor. According to GlobalData, Phase III drugs for Solid Tumor have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sitravatinib malate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sitravatinib malate overview

Sitravatinib malate is under development for the treatment of renal cell carcinoma, gallbladder cancer, advanced biliary tract cancer, oral cavity cancer, gastroesophageal junction carcinoma, non-small cell lung cancer, metastatic hepatocellular carcinoma, renal cell carcinoma, epithelial ovarian carcinoma, liposarcoma, well-differentiated or de-differentiated liposarcoma, soft tissue sarcomas, peripheral nerve sheath Tumor (neurofibrosarcoma), synovial sarcoma, rhabdomyosarcoma,  metastatic uveal melanoma and metastatic melanoma. The drug candidate is administered orally. It is a second generation multi-targeted kinase inhibitor. It inhibits RET, TRK, DDR and EphRs as well as Met, Axl and VEGFRs (VEGFR 1, 2 3), c-Met, PDGFR and KIT. It was under development for squamous cell carcinoma of head and neck, metastatic castrate-resistant prostate cancer with bone metastasis, thymoma and squamous non-small cell lung cancer, endometrial cancer and metastatic urothelial tract cancer (bladder cancer).

The drug candidate was under development for the treatment of esophageal squamous cell carcinoma and metastatic triple negative breast cancer.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Sitravatinib malate’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.